International journal of obesity : journal of the International Association for the Study of Obesity
-
Randomized Controlled Trial Multicenter Study
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years. ⋯ Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.